Bayer’s weedkiller cancer legal settlement offers only fleeting relief to shareholders
German pharmaceutical giant Bayer’s $12.1bn (€10.7bn) settlement to resolve US cancer lawsuits over its flagship weedkiller Roundup and other products offered fleeting relief to investors looking to move on from the legal woes that have hobbled the stock for almost two years.